http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-109942688-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-16 |
| filingDate | 2019-03-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-04-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2021-04-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-109942688-B |
| titleOfInvention | Synthesis and application of polypeptide drug combined with Sox2 protein in targeted mode |
| abstract | The invention discloses synthesis and application of a polypeptide drug in targeted combination with Sox2 protein, and belongs to the technical field of biological medicines. The invention obtains the polypeptide drug which is combined with Sox2 protein in a targeted way through chemical synthesis; the polypeptide drug Peptide42 which is combined with the Sox2 protein in a targeted manner is added into a cell culture medium of an esophageal squamous carcinoma cell KYSE450, and the functions of the polypeptide drug are identified through cell proliferation experiments, scratches, cell invasion and tumor formation experiments, so that the polypeptide drug has the advantages of reduced cell proliferation rate, reduced cell migration capacity and invasion capacity, poor tumor formation capacity, obvious tumor inhibition function and important application value. |
| priorityDate | 2019-03-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 63.